- Home
- ERAS vs GPGI Comparison
ERAS vs GPGI Comparison
Compare ERAS & GPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERAS | GPGI |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | 977 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.4B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERAS | GPGI |
|---|---|---|
| Price | $19.18 | $14.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $14.25 | N/A |
| AVG Volume (30 Days) | ★ 5.5M | 1.8M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.07% |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $768.10 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $11.22 |
| 52 Week High | $24.28 | $25.66 |
Technical Indicators
Market Signals| Indicator | ERAS | GPGI |
|---|---|---|
| Relative Strength Index (RSI) | 73.23 | 52.96 |
| Support Level | $12.36 | $11.30 |
| Resistance Level | $24.28 | $17.59 |
| Average True Range (ATR) | 1.21 | 0.88 |
| MACD | 0.32 | 0.03 |
| Stochastic Oscillator | 90.66 | 29.13 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About GPGI GPGI Inc.
GPGI Inc is a diversified holding permanent capital platform designed to acquire, own, and scale high-quality businesses that hold great positions in good industries.